Avecho Biotechnology Limited (AVEFF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.36 Million AUD | 11.03% |
| 2022 | 3.93 Million AUD | -22.26% |
| 2021 | 5.05 Million AUD | 38.67% |
| 2020 | 3.64 Million AUD | 3.6% |
| 2019 | 3.52 Million AUD | -41.55% |
| 2018 | 6.02 Million AUD | -44.57% |
| 2017 | 10.86 Million AUD | -18.2% |
| 2016 | 13.28 Million AUD | -15.03% |
| 2015 | 15.63 Million AUD | 9.43% |
| 2014 | 14.29 Million AUD | -23.93% |
| 2013 | 18.78 Million AUD | 13.73% |
| 2012 | 16.51 Million AUD | 7.0% |
| 2011 | 15.43 Million AUD | 57.58% |
| 2010 | 9.79 Million AUD | -0.47% |
| 2009 | 9.84 Million AUD | -20.58% |
| 2008 | 12.39 Million AUD | -7.44% |
| 2007 | 13.38 Million AUD | 34.82% |
| 2006 | 9.93 Million AUD | 24.98% |
| 2005 | 7.94 Million AUD | 351.8% |
| 2004 | 1.75 Million AUD | 68.12% |
| 2003 | 1.04 Million AUD | 0.87% |
| 2002 | 1.03 Million AUD | -3.89% |
| 2001 | 1.07 Million AUD | 149.02% |
| 2000 | -2.2 Million AUD | -318.54% |
| 1999 | 1 Million AUD | 113.04% |
| 1998 | -7.72 Million AUD | 83.25% |
| 1997 | -46.1 Million AUD | -585.24% |
| 1996 | -6.72 Million AUD | -117.54% |
| 1995 | 38.36 Million AUD | 3629.35% |
| 1994 | -1.08 Million AUD | -146.69% |
| 1993 | 2.32 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.55 Million AUD | 0.0% |
| 2024 Q1 | 1.55 Million AUD | -4.85% |
| 2023 Q2 | 2.73 Million AUD | 124.49% |
| 2023 Q3 | 469.66 Thousand AUD | -82.84% |
| 2023 Q4 | 1.63 Million AUD | 247.08% |
| 2023 Q1 | 1.21 Million AUD | -42.37% |
| 2023 FY | 4.36 Million AUD | 11.03% |
| 2022 FY | 3.93 Million AUD | -22.26% |
| 2022 Q3 | 899 Thousand AUD | -40.51% |
| 2022 Q1 | 665.57 Thousand AUD | -72.1% |
| 2022 Q2 | 1.51 Million AUD | 127.05% |
| 2022 Q4 | 2.11 Million AUD | 135.31% |
| 2021 Q2 | 1.37 Million AUD | 44.42% |
| 2021 Q1 | 950.72 Thousand AUD | 9.24% |
| 2021 Q4 | 2.38 Million AUD | 137.09% |
| 2021 FY | 5.05 Million AUD | 38.67% |
| 2021 Q3 | 1 Million AUD | -26.71% |
| 2020 Q4 | 870.34 Thousand AUD | -5.8% |
| 2020 FY | 3.64 Million AUD | 3.6% |
| 2020 Q2 | 798.33 Thousand AUD | 56.24% |
| 2020 Q1 | 510.97 Thousand AUD | -31.01% |
| 2020 Q3 | 923.95 Thousand AUD | 15.74% |
| 2019 Q3 | 738.07 Thousand AUD | -30.24% |
| 2019 Q4 | 740.6 Thousand AUD | 0.34% |
| 2019 Q2 | 1.05 Million AUD | 24.86% |
| 2019 FY | 3.52 Million AUD | -41.55% |
| 2019 Q1 | 847.38 Thousand AUD | -33.58% |
| 2018 Q2 | 1.15 Million AUD | -0.0% |
| 2018 Q4 | 1.27 Million AUD | 0.0% |
| 2018 Q3 | 1.27 Million AUD | 9.99% |
| 2018 FY | 6.02 Million AUD | -44.57% |
| 2018 Q1 | 1.15 Million AUD | 0.0% |
| 2017 Q2 | 2.48 Million AUD | -0.0% |
| 2017 Q1 | 2.48 Million AUD | -59.0% |
| 2017 FY | 10.86 Million AUD | -18.2% |
| 2016 Q1 | 3.28 Million AUD | -47.18% |
| 2016 Q3 | 6.05 Million AUD | 84.38% |
| 2016 Q2 | 3.28 Million AUD | -0.0% |
| 2016 Q4 | 6.05 Million AUD | 0.0% |
| 2016 FY | 13.28 Million AUD | -15.03% |
| 2015 Q4 | 6.21 Million AUD | 0.0% |
| 2015 FY | 15.63 Million AUD | 9.43% |
| 2015 Q1 | 4.58 Million AUD | 32.52% |
| 2015 Q2 | 4.58 Million AUD | 0.0% |
| 2015 Q3 | 6.21 Million AUD | 35.74% |
| 2014 Q1 | 1.27 Million AUD | 2.23% |
| 2014 FY | 14.29 Million AUD | -23.93% |
| 2014 Q4 | 3.45 Million AUD | 0.0% |
| 2014 Q3 | 3.45 Million AUD | 171.41% |
| 2014 Q2 | 1.27 Million AUD | 0.0% |
| 2013 Q3 | 3.63 Million AUD | 12.62% |
| 2013 FY | 18.78 Million AUD | 13.73% |
| 2013 Q4 | 1.24 Million AUD | -65.69% |
| 2013 Q2 | 3.22 Million AUD | 0.0% |
| 2013 Q1 | 3.22 Million AUD | 0.0% |
| 2012 FY | 16.51 Million AUD | 7.0% |
| 2011 FY | 15.43 Million AUD | 57.58% |
| 2010 FY | 9.79 Million AUD | -0.47% |
| 2009 FY | 9.84 Million AUD | -20.58% |
| 2008 FY | 12.39 Million AUD | -7.44% |
| 2007 FY | 13.38 Million AUD | 34.82% |
| 2006 FY | 9.93 Million AUD | 24.98% |
| 2005 FY | 7.94 Million AUD | 351.8% |
| 2004 FY | 1.75 Million AUD | 68.12% |
| 2003 FY | 1.04 Million AUD | 0.87% |
| 2002 FY | 1.03 Million AUD | -3.89% |
| 2001 FY | 1.07 Million AUD | 149.02% |
| 2000 FY | -2.2 Million AUD | -318.54% |
| 1999 FY | 1 Million AUD | 113.04% |
| 1998 FY | -7.72 Million AUD | 83.25% |
| 1997 FY | -46.1 Million AUD | -585.24% |
| 1996 FY | -6.72 Million AUD | -117.54% |
| 1995 FY | 38.36 Million AUD | 3629.35% |
| 1994 FY | -1.08 Million AUD | -146.69% |
| 1993 FY | 2.32 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 94.968% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 11.208% |
| SQZ Biotechnologies Company | 85.61 Million USD | 94.9% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 85.224% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 88.279% |
| Mesoblast Limited | 5.9 Million USD | 26.013% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -190.745% |
| Genus plc | 147.7 Million USD | 97.044% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 50.261% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -225.498% |
| Marizyme, Inc. | 19.23 Million USD | 77.304% |
| ContraFect Corporation | 56.88 Million USD | 92.324% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 47.635% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 0.952% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -195.296% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -49.738% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -56.492% |
| MultiCell Technologies, Inc. | 567.42 USD | -769470.865% |
| Accustem Sciences Inc. | 3.74 Million USD | -16.557% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 94.919% |
| EV Biologics, Inc. | 531.96 Thousand USD | -720.867% |
| Q BioMed Inc. | 3.43 Million USD | -27.063% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 82.332% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1020.914% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -66.191% |
| Biomind Labs Inc. | 994.18 Thousand USD | -339.225% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 98.063% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 35.0% |
| Skye Bioscience, Inc. | 13.54 Million USD | 67.768% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -113.144% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 17566.796% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 13.394% |
| IMV Inc. | 37.7 Million USD | 88.42% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 72.726% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -137.955% |
| GB Sciences, Inc. | 1.42 Million USD | -207.404% |
| Alpha Cognition Inc. | 9.7 Million USD | 55.008% |
| HST Global, Inc. | 140.9 Thousand USD | -2998.994% |
| CSL Limited | 3.44 Billion USD | 99.873% |
| Halberd Corporation | 74.84 Thousand USD | -5734.557% |
| Enzolytics Inc. | 2.17 Million USD | -100.353% |
| Resverlogix Corp. | 12.71 Million USD | 65.649% |
| Affymax, Inc. | 39.38 Million USD | 88.913% |
| SYBLEU INC | 160.87 Thousand USD | -2614.326% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -19.612% |
| argenx SE | 1.53 Billion USD | 99.715% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 92.398% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -318.266% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -176.486% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -28.245% |
| AVAX Technologies, Inc. | 7.31 Million USD | 40.266% |
| Zenith Capital Corp. | 8.94 Million USD | 51.172% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.471% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -24965.72% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -77.847% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2446.047% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 95.604% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -148.153% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -121.431% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -134.218% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 59.817% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -127.325% |
| BioStem Technologies, Inc. | 22.97 Million USD | 80.994% |
| ONE Bio Corp. | 6.44 Million USD | 32.235% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2306.094% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -226.988% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -288.182% |
| Agentix Corp. | 1.37 Million USD | -218.329% |
| LadRx Corporation | 3.81 Million USD | -14.558% |
| Cell Source, Inc. | 4.32 Million USD | -0.956% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -951.004% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -372.837% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -372.837% |
| NovAccess Global Inc. | 2.46 Million USD | -77.022% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -81.573% |
| Itoco Inc. | 919.14 Thousand USD | -375.084% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -3.027% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -290.232% |
| Kadimastem Ltd | 2.41 Million USD | -81.182% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1568.424% |
| CytoDyn Inc. | 18.05 Million USD | 75.818% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -17249.513% |
| Mobile Lads Corp. | 554.54 Thousand USD | -687.437% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1884.16% |
| Qrons Inc. | 643.67 Thousand USD | -578.399% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -207.559% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -95.827% |
| Rebus Holdings, Inc. | 664 Thousand USD | -557.635% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -140.415% |
| International Stem Cell Corporation | 5.27 Million USD | 17.156% |
| Bioxytran, Inc. | 3.82 Million USD | -14.307% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -8195.086% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -21365.364% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 87.959% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -169.883% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -493.435% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -40.363% |
| Neutra Corp. | 243.82 Thousand USD | -1690.945% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 74.986% |
| PureTech Health plc | 144.59 Million USD | 96.98% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 78.689% |
| IXICO plc | 4.7 Million USD | 7.23% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 50.361% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 96.291% |
| CSL Limited | 3.89 Billion USD | 99.888% |
| Cellectis S.A. | 97.32 Million USD | 95.513% |